Clinical Trials Logo

Pacemaker Complication clinical trials

View clinical trials related to Pacemaker Complication.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06449079 Not yet recruiting - Heart Failure Clinical Trials

The PICM Risk Prediction Study - Application of AI to Pacing

Start date: July 30, 2024
Phase:
Study type: Observational

Development of pacing induced cardiomyopathy (PICM) is correlated to a high morbidity as signified by an increase in heart failure admissions and mortality. At present a lack of data leads to a failure to identify patients who are at risk of PICM and would benefit from pre-selection to physiological pacing. In the light of the foregoing, there is an urgent need for novel non-invasive detection techniques which would aid risk stratification, offer a better understanding of the prevalence and incidence of PICM in individuals with pacing devices and the contribution of additional risk factors.

NCT ID: NCT03148444 Not yet recruiting - Clinical trials for Infection, Bacterial

Impact of Antibiotic Treatment Following Implantation of Cardiac Electronic Device on Patient's Outcome

Start date: June 1, 2017
Phase: Phase 4
Study type: Interventional

Background: Infection of cardiac implantable electronic device including wound and pouch infection, bacteraemia and endocarditis is a common complication of device insertion. The role of antibiotic prophylaxis in prevention of this complication is well established. Most centres in Israel currently prescribe antibiotics about 5 days following the procedure as well, though clear clinical evidence warranting this practise is lacking. Unnecessary antibiotic treatment can lead to adverse events including allergy, undesirable effects of the antibiotics, establishment of resistance to antibiotics among bacteria and further infections with resistant strains. Objective: The investigators hope to either establish evidence warranting use of post-procedural antibiotic treatment or refuting it. Methods: The investigators intend to recruit about 400 patients a year into both trial group and control group. The trial group will be treated with post-procedural antibiotics during 5 days, while the control group will receive no post-procedural antibiotics. The endpoints of the study will include infections related to the implantable device and proposed adverse effects of the antibiotics. The t-test will be performed in order to evaluate whether benefit exists concerning one of the groups.